OpenBiome GTM brain

category

market profile

• text: The national stool bank stopped distributing its investigational FMT product at the end of 2024, and the organization has since shifted to a foundation model.
• text: Clinicians and researchers need infrastructure, tools and access pathways for microbiome therapies, particularly in recurrent C. diff.

personas

• title: Gastroenterologist or infectious disease clinician
  pains:

  • Patients with recurrent C. diff face gaps in treatment access
  • A clinical FMT program requires donor screening, manufacturing and regulatory expertise
• title: Academic microbiome researcher or principal investigator
  pains:

  • Building stool banking infrastructure and navigating regulation can slow studies
  • Translating microbiome findings into therapies requires partners and funding
• title: Foundation program officer or philanthropic donor
  pains:

  • Needs evidence that grants address meaningful access or research gaps
  • Wants durable benefits from finite philanthropic resources

icp

• text: US hospitals and specialty clinics treating recurrent C. diff or developing microbiome therapy programs; institutional size is not specified.
• text: Academic and nonprofit investigators, healthcare systems and collaborating funders building microbiome research or treatment infrastructure.

message pillars

• text: Expand access to microbiome therapies.
• text: Support research through partnerships and open tools.
• text: Close gaps in C. diff care.

objections

• objection: Can we order an FMT preparation directly from OpenBiome?
  response: The organization says it stopped delivering the investigational treatments after regulatory changes; consult its current resources and access programs.
• objection: How can a foundation help an operational clinical or research program?
  response: Explore its stool banking toolkit, open resources and collaborations, and assess the program's own regulatory requirements.

competitors

• name: Ferring Pharmaceuticals
  why: Offers Rebyota, a regulated microbiota-based option in recurrent C. diff; an adjacent treatment alternative, not a direct foundation equivalent.
• name: BiomeBank
  why: Australian stool bank and microbiome therapy organization working in a related clinical access space.

influencers

• name: Alexander Khoruts
  url: https://journals.sagepub.com/doi/abs/10.1177/17562848241253089
  why: University of Minnesota microbiota program leader and prior collaborator on FMT access.

keywords

• recurrent C diff microbiome treatment
• fecal microbiota transplantation toolkit
• stool bank clinical research
• microbiome research grants
• FMT donor screening
• microbiome therapy access

voice

• Mission-driven
• Science-informed
• Collaborative and hopeful

signals

• text: A hospital is creating an FMT or microbiome therapy program and needs clinical infrastructure.
• text: An investigator or funder is starting a microbiome therapy research initiative.

pricing

motion

channels

• partnerships
• scientific publications
• website
• news and thought leadership

confidence

Founders

• name: Majdi Osman
  title: Founder
  role: Founder
  bio: Co-founder, OpenBiome. Physician scientist researching the role of the microbiome in human health.
• name: Carolyn Edelstein
  title: Founder
  role: Founder
  bio: Carolyn Edelstein is OpenBiome’s Executive Director. She previously worked at Development Innovation Ventures, a program at USAID designed to fund ideas that could improve millions of lives in more cost-effective ways than standard international development approaches. Carolyn helped launch the Global Innovation Fund, a $200M multilateral development fund built on the DIV model, before co-founding OpenBiome.